Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
Child, J. Anthony
Morgan, Gareth J.
Jackson, Graham H.
MetadataShow full item record
AbstractImmunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes of patients with IgD myeloma from UK phase 3 myeloma trials analyzed in 2 groups: old (1980-2002) and recent (2002-2016) clinical trials, based on the time of adoption of novel myeloma therapies. Patients with IgD myeloma comprised 44 of 2789 (1.6%) and 70 of 5773 (1.2%) of the old and recent trials, respectively. Overall, IgD myeloma was associated with male predominance, low-level paraproteinemia (,10g/L), and l light chain preference. The frequency of ultra-high-risk cytogenetics was similar in IgD myeloma compared with other subtypes (4.3% vs 5.3%, P . .99). Despite the old trial series being a younger group (median age: 59 vs 63 years, P 5 .015), there was a higher frequency of bone lesions, advanced stage at diagnosis, worse performance status, and severe renal impairment compared with the recent trials. Furthermore, the early mortality rate was significantly higher for the old trial series (20% vs 4%, P 5 .01). The overall response rate following induction therapy was significantly higher in the recent trials (89% vs 43%, P, .0001), and this was consistent with improved median overall survival (48 months; 95% confidence interval [CI] 35-67 months vs 22 months; 95% CI, 16-29 months). Survival outcomes for IgD myeloma have significantly improved and are now comparable to other myeloma types because of earlier diagnosis, novel therapies, and improved supportive care.
CitationAgbuduwe, C., Iqbal, G., Cairns, D.A. et al. (2022) Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. Blood Advances, 6 (17). pp. 5113-5123.
PublisherAmerican Society of Hematology
PubMed ID35790108 (pubmed)
Description© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
- Authors: Agbuduwe C, Iqbal G, Cairns D, Menzies T, Dunn J, Gregory W, Kaiser M, Owen R, Pawlyn C, Child JA, Davies F, Morgan GJ, Jackson GH, Drayson MT, Basu S
- Issue date: 2022 Sep 13
- IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
- Authors: Djidjik R, Lounici Y, Chergeulaïne K, Berkouk Y, Mouhoub S, Chaib S, Belhani M, Ghaffor M
- Issue date: 2015 Sep
- Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chain disease)--a case report.
- Authors: Rabrenović V, Mijušković Z, Marjanović S, Rabrenović M, Jovanović D, Antić S, Ignjatović L, Petrović M, Pilcević D
- Issue date: 2015 Feb
- IgD paraproteinemias.
- Authors: Tichý M, Matĕja F, Urban P, Matuska M
- Issue date: 1993